Table 2.
Characteristics of eligible studies.
| Author (year) | Country | Study phase | Population | Mean Age year |
Sex (Male %) | Sample Size Study |
Follow up of intervention (Weeks) | Dose (mg) of intervention | Baseline of BMI (kg/m2) | Outcomes |
|---|---|---|---|---|---|---|---|---|---|---|
| Del Prato et al. 2021 (29) | Multi-center (Argentina, Australia, Brazil, Canada, Greece, Israel, Mexico, Poland, Romania, Russia, Slovakia, Spain, Taiwan, and the USA) | 3 | Type 2 diabetes | 63.4 | 62 | 1985 | 52 | once-weekly subcutaneous 5, 10, and 15 mg | 32.6 | Weight |
| Heise et al. 2022 (30) | Germany | 1 | Type 2 diabetes | 61.1 | 31 | 73 | 28 | once-weekly subcutaneous 15 mg | 31.2 | Weight |
| Dahl et al. 2020 (31) | Multi-center (USA, Japan, Czech Republic, Germany, Poland, Puerto Rico, Slovakia, and Spain) | 3 | Type 2 diabetes | 61 | 56 | 475 | 40 | once-weekly subcutaneous 5, 10, and 15 mg | 33.5 | Weight |
| Jastreboff et al. 2022 (32) | Multi-center (Countries not reported( | 3 | Obesity | 45 | 32.6 | 2539 | 72 | once-weekly subcutaneous 5, 10, and 15 mg | 37.9 | Weight |
| Rosenstock et al.2021 (33) | Multi-center (India, Japan, Mexico, and the USA) | 3 | Type 2 diabetes | 54.2 | 52.6 | 478 | 40 | once-weekly subcutaneous 5, 10, and 15 mg | 31.8 | Weight |
| Gastaldelli et al.2022 (34) | Multi-center (Argentina, Austria, Greece, Hungary, Italy, Romania, Spain, and the USA) | 3 | Type 2 diabetes | 56.2 | 74 | 296 | 52 | once-weekly subcutaneous 5, 10, and 15 mg | 33.5 | Weight, BMI, WC |
| Ludvik et al. 2021 (35) | Multi-center (Argentina, Austria, Greece, Hungary, Italy, Poland, Puerto Rico, Romania, South Korea, Spain, Taiwan, Ukraine, and the USA) | 3 | Type 2 diabetes | 57.3 | 55 | 954 | 52 | once-weekly subcutaneous 5, 10, and 15 mg | 33.5 | Weight |
| Frias et al. 2018 (36) | Multi-center (Poland, Puerto Rico, Slovakia, and USA) | 2 | Type 2 diabetes | 56.9 | 54.7 | 262 | 26 | once-weekly subcutaneous 1, 5, 10, and 15 mg | 32.6 | Weight, BMI, WC |
BMI, body mass index; WC, waist circumferences.